Drugmakers’ lobbying spending at 10-year high as Washington targets soaring prices.

The spending by the industry’s main trade group and seven key drugmakers has climbed to a level not seen in a decade. The disclosed outlays by these stakeholders to influence Washington climbed to a total of about $70 million in 2018, the second-highest level ever behind their spending of $87 million in 2009, when Obamacare was getting developed and shaking up the health-care sector.